J
John Grous
Researcher at Memorial Sloan Kettering Cancer Center
Publications - 18
Citations - 7093
John Grous is an academic researcher from Memorial Sloan Kettering Cancer Center. The author has contributed to research in topics: Mesothelin & Neutropenia. The author has an hindex of 10, co-authored 18 publications receiving 6934 citations. Previous affiliations of John Grous include St. Elizabeth's Medical Center & Amgen.
Papers
More filters
Journal ArticleDOI
Gefitinib in Combination With Gemcitabine and Cisplatin in Advanced Non–Small-Cell Lung Cancer: A Phase III Trial—INTACT 1
Giuseppe Giaccone,Roy S. Herbst,Christian Manegold,Giorgio V. Scagliotti,Rafael Rosell,Vincent A. Miller,Ronald B. Natale,Joan H. Schiller,Joachim von Pawel,Anna Pluzanska,Ulrich Gatzemeier,John Grous,Judith S. Ochs,Steven D. Averbuch,Michael K. Wolf,Pamela Rennie,Abderrahim Fandi,David H. Johnson +17 more
TL;DR: Gefitinib in combination with gemcitabine and cisplatin in chemotherapy-naive patients with advanced NSCLC did not have improved efficacy over gemcitABine and cascplatin alone, and the reasons for this remain obscure and require further preclinical testing.
Journal ArticleDOI
Gefitinib in Combination With Paclitaxel and Carboplatin in Advanced Non–Small-Cell Lung Cancer: A Phase III Trial—INTACT 2
Roy S. Herbst,Giuseppe Giaccone,Joan H. Schiller,Ronald B. Natale,Vincent A. Miller,Christian Manegold,Giorgio V. Scagliotti,Rafael Rosell,Ira Oliff,James A. Reeves,Michael K. Wolf,Annetta D. Krebs,Steven D. Averbuch,Judith S. Ochs,John Grous,Abderrahim Fandi,David H. Johnson +16 more
TL;DR: This large, placebo-controlled trial confirmed the favorable gefitinib safety profile observed in phase I and II monotherapy trials and showed no added benefit in survival, time to progression, response rate (TTP), or RR compared with standard chemotherapy alone.
Journal ArticleDOI
Reduction by Granulocyte Colony-Stimulating Factor of Fever and Neutropenia Induced by Chemotherapy in Patients with Small-Cell Lung Cancer
Jeffrey Crawford,Howard Ozer,Ronald G. Stoller,David H. Johnson,Gary H. Lyman,Imad A. Tabbara,Mark G. Kris,John Grous,Vincent J. Picozzi,Gregory Rausch,Roy E. Smith,William J. Gradishar,Anne M. Yahanda,Martha Vincent,Morgan Stewart,John A. Glaspy +15 more
TL;DR: A randomized clinical trial to test the hypothesis that recombinant methionyl granulocyte colony-stimulating factor (G-CSF) can reduce chemotherapy-related neutropenia in patients with cancer and the clinical implications.
Journal ArticleDOI
Effect of Granulocyte Colony-Stimulating Factor on Neutropenia and Associated Morbidity Due to Chemotherapy for Transitional-Cell Carcinoma of the Urothelium
Janice Gabrilove,Ann A. Jakubowski,Ann A. Jakubowski,Howard I. Scher,Howard I. Scher,Cora N. Sternberg,Cora N. Sternberg,George Y. Wong,George Y. Wong,John Grous,John Grous,Alan Yagoda,Alan Yagoda,K. Fain,K. Fain,Malcolm A.S. Moore,Malcolm A.S. Moore,Bayard D. Clarkson,Bayard D. Clarkson,Herbert F. Oettgen,Herbert F. Oettgen,Kirby Alton,Kirby Alton,Karl Welte,Karl Welte,Lawrence M. Souza,Lawrence M. Souza +26 more
TL;DR: It is demonstrated that rhG-CSF is a potent stimulus of normal neutrophil proliferation and maturation and its administration can reduce both the hematopoietic and oral toxicity of chemotherapy.
Journal ArticleDOI
Safety and Survival With GVAX Pancreas Prime and Listeria Monocytogenes–Expressing Mesothelin (CRS-207) Boost Vaccines for Metastatic Pancreatic Cancer
Dung T. Le,Andrea Wang-Gillam,Vincent J. Picozzi,Tim F. Greten,Todd S. Crocenzi,Gregory M. Springett,Michael A. Morse,Herbert J. Zeh,Deirdre Jill Cohen,Robert L. Fine,Beth Onners,Jennifer N. Uram,Daniel A. Laheru,Eric R. Lutz,Sara Solt,Aimee Murphy,Justin Skoble,Ed Lemmens,John Grous,Thomas W. Dubensky,Dirk G. Brockstedt,Elizabeth M. Jaffee +21 more
TL;DR: Heterologous prime/boost vaccination with Cy/GVAX and CRS-207 extended survival for patients with pancreatic cancer, with minimal toxicity.